This separation of astrocytomas into IDHwt and mutated type tumors implies that all hospitals should have access to adequate molecular tests to identify cases of astrocytomas with noncanonical IDH mutations that will not be detected by IDHR132H. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).